FLUOROURACILUM
Neuropathy;Peripheral
Tanta UniversitySmall moleculePhase 2/3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Neuropathy;Peripheral cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pentoxifylline Tanta University | Phase 2/3 | BB |
Calcium folinate pentahydrate Tanta University | Phase 2/3 | BB |
10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one Tanta University | Phase 3 | B |
Lacosamide Danish Pain Research Center | Phase 2 | CCC |
Same molecule, other indications
FLUOROURACILUM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →